One-day protocol for cerebral perfusion reserve with acetazolamide.

UNLABELLED A one-day protocol with a double injection of 99mTc-ECD was introduced for the assessment of cerebral perfusion reserve with acetazolamide (ACZ). The purpose of this study was to investigate the feasibility and effectiveness of this protocol. METHODS Thirty subjects were given double injections of 99mTc-ECD (first dose 370 MBq; second dose 740 MBq) for consecutive brain perfusion studies. Serial dynamic SPECT scans (1 min x 50 frames) were performed with the first set of SPECT data obtained by totaling the data for the frames taken between 5 and 20 min, and the second by subtracting the decay and dose-corrected initial SPECT data from the sum of the data obtained between 35 and 50 min. To evaluate the feasibility and effectiveness of the procedure, 23 of the 30 subjects were injected with ACZ 14 min after the first dose. To evaluate the reproducibility, seven subjects were not given the ACZ. The washout rate (WR) was calculated for three stages (WR1 = from 6 to 14 min, WR2 = from 20 to 28 min, and WR3 = from 36 to 44 min). Regional count increase (percent increase) and the percent count difference between normal and affected side (percent difference) were also calculated. RESULTS Values for WR1, WR2 and WR3 did not show significant differences among the stages (WR1 = -1.43% +/- 6.09%, WR2 = -0.65% +/- 6.57%, and WR3 = -1.60% +/- 4.28%; F-value = 0.33, p-value = 0.72). Reproducibility was excellent (second SPECT = 0.964 x first SPECT; r = 0.997). Mean count increase after ACZ was 21.7%. In patients with unilateral cerebrovascular disease, the percent increase after ACZ loading was significantly greater on the normal side (26.6% +/- 13.0%) than on the affected side (19.3% +/- 13.2%) (p < 0.01), resulting in a significant increase in percent difference (control: 14.3% +/- 10.7%, ACZ: 19.2% +/- 11.5%; p < 0.01). CONCLUSION ECD washout was minimal during the first 50 min after injection and was not affected by ACZ, which supports the feasibility of this protocol. The simple procedure and short acquisition time of this method renders it clinically useful for measuring cerebral perfusion reserve.

[1]  Y. Yonekura,et al.  Evaluation of a double-injection method for sequential measurement of cerebral blood flow with iodine-123-iodoamphetamine. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  J. Mountz,et al.  Regional cerebral blood flow changes in stroke imaged by Tc-99m HMPAO SPECT with corresponding anatomic image comparison. , 1993, Clinical nuclear medicine.

[3]  R. Leroy,et al.  Comparison of technetium-99m-ECD to Xenon-133 SPECT in normal controls and in patients with mild to moderate regional cerebral blood flow abnormalities. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  A. Nunn,et al.  The single-pass cerebral extraction and capillary permeability-surface area product of several putative cerebral blood flow imaging agents. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  A. Thie,et al.  99mTc‐HMPAO‐SPECT With Acetazolamide Challenge to Detect Hemodynamic Compromise in Occlusive Cerebrovascular Disease , 1992, Stroke.

[6]  R. Walovitch,et al.  Intrasubject comparison between technetium-99m-ECD and technetium-99m-HMPAO in healthy human subjects. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  H. Matsuda,et al.  SPECT Evaluation of Brain Perfusion Reserve by the Acetazolamide Test Using Tc‐99m HMPAO , 1991, Clinical nuclear medicine.

[8]  S. Eberl,et al.  Use of technetium-HMPAO to demonstrate changes in cerebral blood flow reserve following carotid endarterectomy. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  B. Holman,et al.  Metabolism of 99mTc-l,l-Ethyl cysteinate dimer in healthy volunteers , 1991, Neuropharmacology.

[10]  J. Adams,et al.  Inhibiting carbonic anhydrase in brain tissue increases the respiratory response to rebreathing CO2 , 1990, Brain Research.

[11]  G Demonceau,et al.  Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, Part 2: Biodistribution and brain imaging in humans. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  D. O'leary,et al.  Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, Part 1: Pharmacology of technetium-99m ECD in nonhuman primates. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  A. Shields,et al.  Cellular sources of thymidine nucleotides: studies for PET. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  O. Schober,et al.  Cerebral dynamics of N-isopropyl-(123I)p-iodoamphetamine. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  O B Paulson,et al.  Effect of acetazolamide on cerebral blood flow and cerebral metabolic rate for oxygen. , 1984, The Journal of clinical investigation.

[16]  A Hauge,et al.  Acute effects of acetazolamide on cerebral blood flow in man. , 1983, Acta physiologica Scandinavica.

[17]  Hanson Ma,et al.  The location of carbonic anhydrase in relation to the blood-brain barrier at the medullary chemoreceptors of the cat. , 1981 .

[18]  N. Lassen,et al.  Retention of 99mTc-bicisate in the human brain after intracarotid injection. , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  N. Sadato,et al.  SPECT images of technetium-99m-ethyl cysteinate dimer in cerebrovascular diseases: comparison with other cerebral perfusion tracers and PET. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  N. Lassen,et al.  Characterization of 99mTc-bicisate as an agent for the measurement of cerebral blood flow with SPECT. , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  S. Tanada,et al.  Kinetic behavior of technetium-99m-HMPAO in the human brain and quantification of cerebral blood flow using dynamic SPECT. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  H. Deininger,et al.  [The value of the acetazolamide stimulation test with 99mTc-HMPAO-SPECT in reversible cerebrovascular insufficiency]. , 1991, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[23]  S. Pauwels,et al.  Production of [2-11C]thymidine for quantification of cellular proliferation with PET. , 1991, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[24]  N. Lassen Pathophysiology of Brain Ischemia as It Relates to the Therapy of Acute Ischemic Stroke , 1990, Clinical neuropharmacology.

[25]  N. Lassen,et al.  Cerebral blood-flow tomography: xenon-133 compared with isopropyl-amphetamine-iodine-123: concise communication. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  M. Hanson,et al.  The location of carbonic anhydrase in relation to the blood‐brain barrier at the medullary chemoreceptors of the cat. , 1981, The Journal of physiology.

[27]  J. Cleaver Thymidine metabolism and cell kinetics , 1967 .